TTT-AI is happy to announce yet another great investment in Aiosyn. Aiosyn is developing a diagnostics platform that uses artificial intelligence to support pathologists with more accurate and efficient clinical diagnostics. A new investment round of EUR 2 million, led by Health Innovations together with Oost NL and LUMO Labs TTT-AI fund II, enables Aiosyn to further develop their platform and accelerate the time to market.

Aiosyn, a diagnostics platform developer based in the Netherlands, has raised €2m ($2.4m) in a funding round led by Health Innovations and featuring participation from Oost NL and LUMO Labs. The company is creating an AI-powered platform to support pathologists with clinical diagnostics, with the funds to be used to accelerate the launch of its first product. Aiosyn's algorithms will work alongside pathologists to boost the efficiency of the digital pathology workflow, with the aim of improving the diagnostic process. CEO Patrick de Boer said the investment would enable the firm to "lay the foundation for the future product roadmap.

AI helps with better diagnosis

Patrick de Boer, CEO and co-founder of Aiosyn, explains: “The field of pathology is challenged by a growing workload and a shortage of pathologists. Aiosyn develops algorithms that work in close synergy with pathologists to improve the digital pathology workflow and clinical diagnostic tasks. With this investment, we can accelerate our first product launch and lay the foundation for the future product roadmap. We’re happy that existing investors Oost NL and LUMO labs and now Health Innovations support us during this journey.”

Last year Aiosyn has worked on developing two algorithms and setting up its certification process. Recently they achieved ISO:13485 certification as a first step towards developing high-quality AI-based medical devices.